Hemp-Focused CV Sciences Expands Via New Cannabis Acquisition, Here's What Investors Need To Know
Hemp-Focused CV Sciences Expands Via New Cannabis Acquisition, Here's What Investors Need To Know
CV Sciences, Inc. (OTCQB:CVSI) a hemp-focused wellness company announced on Thursday it's acquiring Extract Labs, Inc., a manufacturer and distributor of premium cannabinoid products including gummies, topicals and tinctures.
CV Sciences, Inc. (OTCQB:CVSI) 是一家專注於大麻的健康公司，週四宣佈將收購 Extract Labs, Inc.，該公司是一家制造和分銷優質大麻產品的公司，包括糖果、外用藥膏和酊劑。
What Happened
發生了什麼
The company noted that it has entered into a definitive agreement to purchase Extract Labs for the following considerations:
該公司表示已簽署最終協議，以以下條件購買 Extract Labs：
- cash payment of $400,000, less the amount of certain holdbacks and adjustments; and
- the issuance of shares of CV Sciences' common stock valued at $1 million based on the sixty-day volume weighted average price of CV Sciences' common stock.
- 現金支付 $400,000，扣除某些保留款和調整金額；以及
- 以 $100萬 的估值發行 CV Sciences 普通股，基於 CV Sciences 普通股的六十天成交量加權平均價格。
Additionally, under the deal, Extract Labs sellers will be eligible to receive up to $600,000 of additional shares of CV Sciences' common stock if Extract Labs satisfies certain revenue targets during the first year following the closing date.
此外，根據協議，如果 Extract Labs 在交易完成後的第一年內滿足某些營業收入目標，Extract Labs 的賣方將有資格獲得高達 $600,000 的額外 CV Sciences 普通股。
Read Also: CV Sciences Q3: Revenue Stable Amid New Launches, Financing
另請閱讀：CV Sciences 第三季度：在新產品發佈和融資中營業收入穩定
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 訂閱本新聞快訊，每天免費獲取Benzinga獨家分析和大麻股行業及市場的最新資訊。如果您對業務認真，不容錯過。在這裏訂閱我們的新聞簡報。
Why It Matters
這爲以下原因非常重要
Extract Labs' branded products are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C).
Extract Labs的品牌產品通過從企業對企業(B2B)到企業對消費者(B2C)的多種銷售渠道進行銷售。
Moreover, Extract Labs, which is GMP-certified and FDA-registered, has operational flexibility that allows for low to large minimum order quantity production runs, making the use of capital and the ability to increase speed to market for new product development more efficient.
此外，Extract Labs具備GMP認證並註冊於FDA，擁有運營靈活性，可以在低至大量最小訂單量的生產中運作，提高了資本的使用效率和新產品開發的市場速度。
CV Sciences says it expects the transaction will create the opportunity to increase its sales to current and new clients.
CV Sciences表示，他們預計此次交易將爲增加對現有客戶和新客戶的銷售創造機會。
"The acquisition synergies are expected to increase our revenue and customer base, allow us to leverage our key assets, optimize operations and processes, and drive long-term growth and shareholder value," said CEO Joseph Dowling. "Extract Labs is a stand-alone profitable business and our plan is to increase its existing revenue base and further leverage its existing capacity."
"收購的協同效應預計將增加我們的營業收入和客戶基礎，使我們能夠利用我們的關鍵資產，優化運營和流程，推動長期增長和股東價值，" CEO Joseph Dowling表示。"Extract Labs是一項獨立盈利的業務，我們的計劃是增加其現有的營業收入基礎，並進一步利用其現有的產能。"
What's Next
接下來怎麼做
The acquisition is expected to close during the first quarter of 2025, subject to customary conditions precedent. The company also plans to in-source production of certain of its key products.
預計收購將在2025年第一季度完成，需遵循慣例的先決條件。該公司還計劃自主生產其某些關鍵產品。
"We are planning to in-source the manufacturing of select +PlusCBD branded products providing an opportunity for meaningful cost savings. Extract Labs manufacturing capability will provide us with greater control over our supply chain and accelerate our new product development cycle," Dowling said.
"我們計劃自主生產部分+PlusCBD品牌產品，以提供實現重要成本節約的機會。Extract Labs的製造能力將使我們對供應鏈有更大的控制力，並加快我們的新產品開發週期，" Dowling說道。
CVSI Price Action
CVSI 價格走勢
CV Sciences' shares traded 9.09% lower at $0.04 per share after the market close on Thursday afternoon.
CV Sciences的股票在週四下午收盤後交易價格下降了9.09%，每股價格爲0.04美元。
- Hemp-Focused CV Sciences Reports Flat Revenue And Over 8% YoY Increase In Gross Profit In Q2
- 以大麻爲重點的CV Sciences報告第二季度營業收入持平，毛利潤同比增長超過8%。
譯文內容由第三人軟體翻譯。
